ÖZ
Amaç: Kalprotektin, fagositlerin sitoplazmasında bulunan ve inflamatuar yanıtta ekstrasellüler matrikse salınan bir proteindir. Önceki çalışmalar, kalp yetersizliği ve akut koroner sendromlu hastalarda plazma kalprotektin düzeylerinin yüksek olduğunu göstermiştir. Bu çalışmada, plazma kalprotektin düzeylerinin fonksiyonel ve dejeneratif mitral yetersizliği etiyolojilerine göre farklılık gösterip göstermediği araştırıldı. Yöntem: Çalışmaya şiddetli fonksiyonel mitral yetersizliği (FMY) tanısı alan 24 hasta, şiddetli dejeneratif mitral yetersizliği (DMY) tanısı alan 36 hasta ve 22 sağlıklı kontrol dahil edildi. Tüm katılımcılara ekokardiyografi uygulandı. Plazma kalprotektin düzeyleri enzyme-linked immunosorbent assay (ELISA) yöntemiyle ölçüldü. Bulgular: Yaş, cinsiyet ve kardiyovasküler risk faktörleri açısından gruplar arasında anlamlı farklılık saptanmadı. Plazma kalprotektin düzeyleri FMY grubunda hem DMY grubuna hem de kontrol grubuna göre anlamlı derecede yüksek bulundu (sırasıyla p<0.001 ve p=0.002). Sonuç: Bulgularımız, şiddetli FMY hastalarında plazma calprotectin düzeylerinin belirgin şekilde arttığını göstermektedir. Kalprotektin düzeyleri, mitral yetersizliğinden ziyade kalp yetersizliği ile daha fazla ilişkili görünmektedir. Anahtar Kelimeler: Kalp yetersizliği, mitral yetersizliği, kalprotektin, akut koroner sendrom
Cite this Article As :
Gurbuz AS, Ozturk S, Kilicgedik A, Sahin AT, Yaman A. The Role of Plasma Calprotectin Levels in Patients with Severe Mitral
Regurgitation. Selcuk Med J 2025;41(3): 152-157
1. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):524. doi: 10.1016/j.rec.2022.05.006.
2. Gruson D, Ahn SA, Rousseau MF. Biomarkers of inflammation and cardiac remodeling: the quest of relevant companions for the risk stratification of heart failure patients is still ongoing. Biochem Med (Zagreb). 2011;21(3):254-63. doi: 10.11613/bm.2011.035.
3. Hessian PA, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol. 1993 Feb;53(2):197-204.
4. Volz HC, Laohachewin D, Seidel C, et al. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling. Basic Res Cardiol. 2012 Mar;107(2):250. doi: 10.1007/s00395-012-0250-z.
5. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006 May 16;113(19):2278-84. doi: 10.1161/CIRCULATIONAHA.105.607333.
6. Altwegg LA, Neidhart M, Hersberger M, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007 Apr;28(8):941-8. doi: 10.1093/eurheartj/ehm078.
7. Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan;155(1):49-55. doi: 10.1016/j.ahj.2007.08.018.
8. ensen LJ, Pedersen S, Bjerre M, et al. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol. 2010 Apr;23(2):123-9. doi: 10.1111/j.1540-8183.2010.00532.x.
9. Jensen LJ, Kistorp C, Bjerre M, et al. Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. Eur J Prev Cardiol. 2012 Oct;19(5):999-1004. doi: 10.1177/1741826711421078.
10. Ma LP, Haugen E, Ikemoto M, et al. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int J Cardiol. 2012 Feb 23;155(1):26-32. doi: 10.1016/j.ijcard.2011.01.082.
11. Feigenbaum H, Armstrong WF, Ayan T. Feigenbaum’s Echocardiography. 6th ed. Philadelphia: Lippincotts Williams&Wilkins; 2005. p. 355
12. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003 Jul;16(7):777-802. doi: 10.1016/S0894-7317(03)00335-3.
13. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932.
14. Clavel MA, Tribouilloy C, Vanoverschelde JL, et al. Association of B-Type Natriuretic Peptide With Survival in Patients With Degenerative Mitral Regurgitation. J Am Coll Cardiol. 2016 Sep 20;68(12):1297-307. doi: 10.1016/j.jacc.2016.06.047.
15. Peng WH, Jian WX, Li HL, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011 May 18;10:41. doi: 10.1186/1475-2840-10-41.
16. Bruhn LV, Lauridsen KG, Schmidt AS, et al. Elevated calprotectin in patients with atrial fibrillation with and without heart failure. Scand J Clin Lab Invest. 2017 May;77(3):210-215. doi: 10.1080/00365513.2017.1292364.
Research Paper
View as PDF
Keywords
Kalp yetmezliği, Akut Koroner Sendrom, Kalprotektin, Mitral Yetersizliği
